BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dowall SD, Bosworth A, Rayner E, Taylor I, Landon J, Cameron I, Coxon R, Al Abdulla I, Graham VA, Hall G, Kobinger G, Hewson R, Carroll MW. Post-exposure treatment of Ebola virus disease in guinea pigs using EBOTAb, an ovine antibody-based therapeutic. Sci Rep 2016;6:30497. [PMID: 27465308 DOI: 10.1038/srep30497] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Luke T, Bennett RS, Gerhardt DM, Burdette T, Postnikova E, Mazur S, Honko AN, Oberlander N, Byrum R, Ragland D, St Claire M, Janosko KB, Smith G, Glenn G, Hooper J, Dye J, Pal S, Bishop-Lilly KA, Hamilton T, Frey K, Bollinger L, Wada J, Wu H, Jiao JA, Olinger GG, Gunn B, Alter G, Khurana S, Hensley LE, Sullivan E, Jahrling PB. Fully Human Immunoglobulin G From Transchromosomic Bovines Treats Nonhuman Primates Infected With Ebola Virus Makona Isolate. J Infect Dis 2018;218:S636-48. [PMID: 30010950 DOI: 10.1093/infdis/jiy377] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
2 Connor J, Kobinger G, Olinger G. Therapeutics Against Filovirus Infection. Curr Top Microbiol Immunol 2017;411:263-90. [PMID: 28653190 DOI: 10.1007/82_2017_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 Fell R, Potter JA, Yuille S, Salguero FJ, Watson R, Ngabo D, Gooch K, Hewson R, Howat D, Dowall S. Activity of a Carbohydrate-Binding Module Therapy, Neumifil, against SARS-CoV-2 Disease in a Hamster Model of Infection. Viruses 2022;14:976. [DOI: 10.3390/v14050976] [Reference Citation Analysis]
4 Schmidt R, Beltzig LC, Sawatsky B, Dolnik O, Dietzel E, Krähling V, Volz A, Sutter G, Becker S, von Messling V. Generation of therapeutic antisera for emerging viral infections. NPJ Vaccines 2018;3:42. [PMID: 30323953 DOI: 10.1038/s41541-018-0082-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
5 Banadyga L, Wong G, Qiu X. Small Animal Models for Evaluating Filovirus Countermeasures. ACS Infect Dis 2018;4:673-85. [PMID: 29457711 DOI: 10.1021/acsinfecdis.7b00266] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
6 Rosamilia A, Jacca S, Tebaldi G, Tiberti S, Franceschi V, Macchi F, Cavirani S, Kobinger G, Knowles DP, Donofrio G. BoHV-4-based vector delivering Ebola virus surface glycoprotein. J Transl Med 2016;14:325. [PMID: 27881138 DOI: 10.1186/s12967-016-1084-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Dowall SD, Jacquot F, Landon J, Rayner E, Hall G, Carbonnelle C, Raoul H, Pannetier D, Cameron I, Coxon R, Al Abdulla I, Hewson R, Carroll MW. Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product. Sci Rep 2017;7:4099. [PMID: 28642489 DOI: 10.1038/s41598-017-03910-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
8 Zhang Y, Wei Y, Li Y, Wang X, Liu Y, Tian D, Jia X, Gong R, Liu W, Yang L. IgY antibodies against Ebola virus possess post-exposure protection in a murine pseudovirus challenge model and excellent thermostability. PLoS Negl Trop Dis 2021;15:e0008403. [PMID: 33711011 DOI: 10.1371/journal.pntd.0008403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 [DOI: 10.1101/2020.05.21.108159] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Findlay-wilson S, Easterbrook L, Smith S, Pope N, Humphries G, Schuhmann H, Ngabo D, Rayner E, Otter AD, Coleman T, Hicks B, Graham VA, Halkerston R, Apostolakis K, Taylor S, Fotheringham S, Horton A, Tree JA, Wand M, Hewson R, Dowall SD. Development of a cost-effective ovine antibody-based therapy against SARS-CoV-2 infection and contribution of antibodies specific to the spike subunit proteins. Antiviral Research 2022. [DOI: 10.1016/j.antiviral.2022.105332] [Reference Citation Analysis]